- Home
- GOSS vs FOF Comparison
GOSS vs FOF Comparison
Compare GOSS & FOF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GOSS
- FOF
- Stock Information
- Founded
- GOSS 2015
- FOF 2006
- Country
- GOSS United States
- FOF United States
- Employees
- GOSS N/A
- FOF N/A
- Industry
- GOSS Biotechnology: Pharmaceutical Preparations
- FOF Investment Managers
- Sector
- GOSS Health Care
- FOF Finance
- Exchange
- GOSS Nasdaq
- FOF Nasdaq
- Market Cap
- GOSS 347.8M
- FOF 354.8M
- IPO Year
- GOSS 2019
- FOF N/A
- Fundamental
- Price
- GOSS $2.47
- FOF $13.04
- Analyst Decision
- GOSS Strong Buy
- FOF
- Analyst Count
- GOSS 4
- FOF 0
- Target Price
- GOSS $8.50
- FOF N/A
- AVG Volume (30 Days)
- GOSS 3.1M
- FOF 58.7K
- Earning Date
- GOSS 08-05-2025
- FOF 01-01-0001
- Dividend Yield
- GOSS N/A
- FOF 9.07%
- EPS Growth
- GOSS N/A
- FOF N/A
- EPS
- GOSS N/A
- FOF N/A
- Revenue
- GOSS $40,237,000.00
- FOF N/A
- Revenue This Year
- GOSS N/A
- FOF N/A
- Revenue Next Year
- GOSS $30.65
- FOF N/A
- P/E Ratio
- GOSS N/A
- FOF N/A
- Revenue Growth
- GOSS N/A
- FOF N/A
- 52 Week Low
- GOSS $0.66
- FOF $9.59
- 52 Week High
- GOSS $2.65
- FOF $11.75
- Technical
- Relative Strength Index (RSI)
- GOSS 68.08
- FOF 58.11
- Support Level
- GOSS $2.38
- FOF $13.01
- Resistance Level
- GOSS $2.65
- FOF $13.13
- Average True Range (ATR)
- GOSS 0.15
- FOF 0.09
- MACD
- GOSS 0.03
- FOF -0.01
- Stochastic Oscillator
- GOSS 76.67
- FOF 59.05
About GOSS Gossamer Bio Inc.
Gossamer Bio Inc is a clinical-stage biopharmaceutical company. It focuses on discovering, acquiring, developing, and commercializing therapeutics in the disease areas of immunology, inflammation, and oncology. The company pipeline products include Seralutinib, which address the cellular overgrowth, fibrosis, and vascular remodeling which underlie PAH (pulmonary arterial hypertension); GB004, for the treatment of inflammatory bowel disease, including ulcerative colitis and Crohn's disease; GB1275, for the treatment of oncology indications; and GB001, for the treatment of moderate-to-severe eosinophilic asthma.
About FOF Cohen & Steers Closed-End Opportunity Fund Inc.
Cohen & Steers Closed-end Opp Fd Inc is a diversified, closed-ended management investment company. Its investment objective is to achieve a total return, consisting of high current income and potential capital appreciation.